Mini review-vanadium-induced neurotoxicity and possible targets
Madhuri Ramji Jaiswal1, Pravin Popatrao Kale2
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. L. Mehta Road, Mithibai campus, Vile Parle west, Mumbai, Maharashtra, 400056, India.
Summary
Vanadium exposure can cause neurotoxicity and memory loss. Targeting protein P38 mitogen-activated protein kinase and oxidative stress may offer a way to treat this vanadium-induced neurotoxicity.
Area of Science:
- Environmental Science
- Toxicology
- Neuroscience
Background:
- Vanadium, a naturally occurring transition metal, exhibits both therapeutic and toxic properties.
- Known therapeutic applications include antidiabetic, antitumor, and antiparasitic activities.
- However, prolonged exposure to vanadium can lead to significant neurotoxicity, potentially causing memory impairment.
Purpose of the Study:
- To review the mechanisms underlying vanadium-induced neurotoxicity.
- To explore the role of oxidative stress and inflammation in neuronal damage caused by vanadium.
- To identify potential therapeutic targets for mitigating vanadium neurotoxicity.
Main Methods:
- Literature review focusing on vanadium toxicology and neuroinflammation.
- Analysis of studies investigating the role of protein P38 mitogen-activated protein kinase (MAPK) in neurotoxicity.
- Examination of research on oxidative stress markers in vanadium exposure.
Main Results:
- Vanadium exposure is linked to neurotoxic effects, including memory impairment.
- Oxidative stress and inflammation in neuronal cells are proposed mechanisms for this toxicity.
- Protein P38 MAPK is implicated as a key mediator in the neurotoxic pathway.
Conclusions:
- Vanadium-induced neurotoxicity is a significant concern, particularly with long-term exposure.
- Targeting protein P38 MAPK and mitigating oxidative stress present promising therapeutic strategies.
- Further research into these pathways could lead to effective treatments for vanadium neurotoxicity.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
756
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
756
Electron Transport Chain: Complex I and II
18.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.3K


